Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-09-25 00:00:00 ET · period of report 2024-09-21 · accession 0001787306-24-000133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-25 | 2024-09-24 | ARQT | Topper David Joseph | CFO | S - Sale | $9.48 | -11.6K | 158.4K | -7% | -$110.2K | |
| 2024-09-25 | 2024-09-21 | ARQT | Topper David Joseph | CFO | A - Grant | $0.00 | +60.0K | 170.0K | +55% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-24 | S | D | 11,626 | $9.48 | 158,374 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.40 to $9.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-09-21 | A | A | 60,000 | $0.00 | 170,000 | D | — | — | (F1) Represents Performance Stock Units ("PSUs"), initially granted on June 20, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on September 21, 2024 (the "Vesting Commencement Date"). Therefore, 50% of the shares vested on September 21, 2024 and the remaining 50% of the shares vest on September 21, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date. |